Spread awareness by sharing and learning more: Post the social media graphic, Listen to past conference sessions, and this webinar. Find these and other opportunities here: Caregiver Health and Wellness section.
FOR IMMEDIATE RELEASE
November 25, 2020
Traveling with a rare disease
An experimental complement inhibitor C5 monoclonal antibody.
VIDEO
Description:
Treatment Approaches in AML: Key Testing for Personalized Care from Patient Empowerment Network on Vimeo.
Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative.
Chetasi Talati, MD
Chetasi Talati, MD
The recently-approved hypomethylating treatment, Inoqvi, is a daily oral version of two IV or subcutaneous medications. Listen to Dr. Amer Zeidan of Yale Cancer Center explain which MDS patients could qualify, and what it means for their treatment at the link.
Since treatment in July 2019, I have still been transfusion-dependent, receiving both blood and platelets. I get so short of breath when my blood is low. I really hate this disease. Because I’m still transfusion-dependent, I go back and forth for labs, doctor’s appointments, and transfusions.
